Pharmaceuticals 2014, 7(1), 18-28; doi:10.3390/ph7010018
Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient
1
Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, 736 Cambridge Street, Brighton, MA 02135, USA
2
Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street Suite 8E, Boston, MA 02115, USA
â€
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 18 October 2013 / Revised: 16 December 2013 / Accepted: 24 December 2013 / Published: 30 December 2013
(This article belongs to the Special Issue Immunosuppressant Drugs)
View Full-Text
|
Download PDF [191 KB, uploaded 31 December 2013]
Abstract
Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primarily with immunosuppressive therapy. Herein, we review the current literature, detailing the promise and pitfalls of the recommended immunosuppressive therapy for these challenging diseases. View Full-TextKeywords:
autoimmune liver disease; autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; overlap syndrome
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Scifeed alert for new publications
Never miss any articles matching your research from any publisher- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Related Articles
Article Metrics
Comments
[Return to top]
Pharmaceuticals
EISSN 1424-8247
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert